Abstract
The most deadly outbreak of Escherichia coli O104:H4 occurred in Europe in 2011. Here, we evaluated the effects of the retrograde trafficking inhibitor Retro-2(cycl) in a murine model of E. coli O104:H4 infection. Systemic treatment with Retro-2(cycl) significantly reduced body weight loss and improved clinical scores and survival rates for O104:H4-infected mice. The present data established that Retro-2(cycl) contributes to the protection of mice against O104:H4 infection and may represent a novel approach to limit Shiga toxin-producing Escherichia coli (STEC)-induced toxicity.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Benzamides / pharmacology*
-
Benzamides / therapeutic use
-
Chlorocebus aethiops
-
Disease Models, Animal
-
Disease Outbreaks
-
Enterohemorrhagic Escherichia coli / drug effects*
-
Enterohemorrhagic Escherichia coli / genetics
-
Enterohemorrhagic Escherichia coli / pathogenicity
-
Escherichia coli Infections / drug therapy*
-
Escherichia coli Infections / epidemiology
-
Europe
-
HeLa Cells
-
Hemolytic-Uremic Syndrome / drug therapy*
-
Hemolytic-Uremic Syndrome / prevention & control
-
Humans
-
Mice
-
Mice, Inbred BALB C
-
Shiga Toxin 2 / antagonists & inhibitors*
-
Thiophenes / pharmacology*
-
Thiophenes / therapeutic use
-
Vero Cells
Substances
-
2-(((5-methyl-2-thienyl)methylene)amino)-N-phenylbenzamide
-
Benzamides
-
Shiga Toxin 2
-
Thiophenes